💼 Scenario
MedPharm is a pharmaceutical company conducting 35 concurrent clinical trials across 200 research sites in 15 countries. The FDA has issued a warning letter citing data integrity concerns in two completed trials, threatening to delay new drug approvals worth an estimated $800 million in annual revenue.
Investigation reveals that 4.5% of patient records contain transcription errors from paper-based source documents, data entry timestamps show implausible patterns suggesting batch entry rather than real-time recording, and 8% of laboratory results fail cross-validation checks against acceptable ranges. Additionally, different research sites use varying interpretations of the clinical trial protocol, leading to inconsistent data collection.
The VP of Clinical Operations must implement a data quality program that satisfies FDA requirements under 21 CFR Part 11 (electronic records and signatures) while not impeding the pace of ongoing trials. The company also needs to remediate data quality issues in the two flagged trials before the FDA reinspection in six months.